Program
EYE201
A development code. Also written as “MK-8748” and “Tiespectus”.
Its studies are mostly in Diabetic Retinopathy · Wet Macular Degeneration · Retinal Vein Occlusion, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 54 open or running | phase 3since Feb 23, 2026 | Oct 28, 2024 | Jun 30, 2028phase 3 · NCT07440225 |
- Named in Merck’s own pipeline as
MK-8748
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 28, 2024First study: phase 2 study in Retinal Vein OcclusionFirst studyNCT06664502 · 38 enrolled · United States, Puerto Rico
- Feb 23, 2026Phase 3 study in Macular DegenerationPhase 3 reachedNCT07440225 · 960 planned · United States, Argentina, Australia and more
- Mar 23, 2026Phase 3 study in Macular DegenerationNCT07496567 · 960 planned · United States, Brazil, Colombia and more
- Jul 10, 20262 phase 3 studies in Diabetic RetinopathyNCT07705607, NCT07705555
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Macular DegenerationNCT07440225
- Jul 31, 2028Primary completion: phase 3 study in Macular DegenerationNCT07496567
- Oct 31, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07705555
- Nov 30, 2028Primary completion: phase 3 study in Diabetic RetinopathyNCT07705607
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07705607Diabetic Retinopathy · United States, Argentina, Israel and more | 3 | Recruiting | Nov 30, 2028 | 1,104 |
| NCT07705555Diabetic Retinopathy · United States, Argentina, Australia and more | 3 | Recruiting | Oct 31, 2028 | 960 |
| NCT07496567Macular Degeneration · United States, Brazil, Colombia and more | 3 | Recruiting | Jul 31, 2028 | 960 |
| NCT07440225Macular Degeneration · United States, Argentina, Australia and more | 3 | Recruiting | Jun 30, 2028 | 960 |
| NCT06664502Retinal Vein Occlusion · United States, Puerto Rico | 2 | Completed | Mar 25, 2026 | 38 |
How it is read
Names in the registry
- “MK-8748”, 2 entries
- “Tiespectus”, 2 entries
- “EYE201”, 1 entry
Codes read as this program: MK8748, EYE201.
Conditions, from the studies’ own filings
- Diabetic Retinopathy, 2 studies
- Wet Macular Degeneration, 2 studies
- Retinal Vein Occlusion, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.